echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Iso's example of early conversion, more benefits, high-risk multiple myeloma case analysis

    Iso's example of early conversion, more benefits, high-risk multiple myeloma case analysis

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Multiple myeloma (MM) is highly heterogeneous, and high-risk multiple myeloma (HRMM) often has a poor prognosis.



    Professor Liu Yan

    • Deputy Director of the First Department of Hematology, Zibo Central Hospital, Deputy Chief Physician

    • Member of the Hematologist Branch of Shandong Medical Doctor Association

    • Member of the Hematology and Tumor Professional Committee of Shandong Anti-Cancer Association

    • Member of the Hematology Professional Committee of Shandong Geriatrics Association

    • Member of Blood Immunity Branch of Shandong Society of Immunology

    • Chairman of the Blood Professional Committee of Zibo Geriatrics Association


    • A patient with HRMM treated with VRd regimen (bortezomib, lenalidomide, dexamethasone) developed adverse events such as rash and peripheral neuritis



    In recent years, with the continuous launch of new drugs, the overall prognosis of MM patients has improved significantly, but HRMM patients are prone to progression and have poor prognosis, and more effective individualized treatment regimens are urgently needed



    references

    [1] Manda S, et al.



    Edit: Moon Reviewer: Janet Typesetting: siqili Execution: siqili



    "

    Click "Read the original text" at the end of the article to view the full content 

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.